AI Article Synopsis
- The study aimed to assess the long-term effectiveness of three treatments for panic disorder: cognitive-behavioral therapy (CBT), selective serotonin reuptake inhibitor (SSRI) pharmacotherapy, and a combination of both.
- During the one-year treatment, significant improvements in anxiety levels, coping abilities, and overall health-related quality of life were reported across all treatment groups.
- Although CBT + SSRI showed some initial superiority in patient satisfaction, all treatment methods maintained their benefits over time, with no significant differences in effectiveness at follow-up assessments.
Article Abstract
Objective: To establish the long-term effectiveness of 3 treatments for DSM-IV panic disorder with or without agoraphobia: cognitive-behavioral therapy (CBT), pharmacotherapy using a selective serotonin reuptake inhibitor (SSRI), or the combination of both (CBT + SSRI). As a secondary objective, the relationship between treatment outcome and 7 predictor variables was investigated.
Method: Patients were enrolled between April 2001 and September 2003 and were randomly assigned to treatment. Academic and nonacademic clinical sites participated. Each treatment modality lasted 1 year. Pharmacotherapists were free to choose between 5 SSRIs currently marketed in The Netherlands. Outcome was assessed after 9 months of treatment (posttest 1), after discontinuation of treatment (posttest 2), and 6 and 12 months after treatment discontinuation (follow-up 1 and follow-up 2).
Results: In the sample (N = 150), 48% did not suffer from agoraphobia or suffered from only mild agoraphobia, while 52% suffered from moderate or severe agoraphobia. Patients in each treatment group improved significantly from pretest to posttest 1 on the primary outcome measures of level of anxiety (P < .001), degree of coping (P < .001), and remitter status (P < .001), as well as on the secondary outcome measures of depressive symptomatology (P < .001), and from pretest to posttest 2 for health-related quality of life (P < .001). Gains were preserved from posttest 2 throughout the follow-up period. Some superiority of CBT + SSRI and SSRI as compared with CBT was observed at posttest 1. However, at both follow-ups, differences between treatment modalities proved nonsignificant. Client satisfaction appeared to be high at treatment endpoint, while patients receiving CBT + SSRI appeared slightly (P < .05) more satisfied than those receiving CBT only.
Conclusions: No fall-off in gains was observed for either treatment modality after treatment discontinuation. SSRIs were associated with adverse events. Gains produced by CBT were slower to emerge than those produced by CBT + SSRI and SSRI, but CBT ended sooner.
Trial Registration: Netherlands Trial Register (www.trialregister.nl) Identifier: ISRCTN8156869.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4088/JCP.08m04681blu | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neural Markers of Treatment Response in Pediatric Anxiety and PTSD.
Curr Top Behav Neurosci
December 2024
Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA.
Pediatric anxiety disorders and post-traumatic stress disorder (PTSD) are associated with elevated threat sensitivity and impaired emotion regulation, accompanied by dysfunction in the neural circuits involved in these processes. Despite established treatments like cognitive behavioral therapy (CBT) and selective serotonin reuptake inhibitors, many children do not achieve remission, underscoring the importance of understanding the neurobiological underpinnings of these disorders. This review synthesizes current research on the neural predictors of treatment response and the neurofunctional changes associated with treatment in pediatric anxiety and PTSD during threat and reward processing.
View Article and Find Full Text PDF[Expectancies and SSRI treatment of social anxiety disorder].
Lakartidningen
November 2024
fil dr, professor, institutionen för psykologi, Uppsala universitet.
Article Synopsis
- - The effectiveness of escitalopram for social anxiety disorder is significantly impacted by patient expectations, with communication playing a key role in enhancing treatment outcomes.
- - Providing accurate information about the drug's effectiveness led to much better clinical results compared to misinformation, even though serotonin transporter levels were similar across treatment approaches.
- - There was a strong link between improved anxiety outcomes and decreased dopamine transporter availability in patients receiving accurate SSRI treatment, while CBT with a placebo showed the opposite relationship, highlighting different mechanisms of improvement.
Advances in Pediatric Obsessive-Compulsive Disorder (OCD) Treatment: A Comprehensive Narrative Review.
Cureus
August 2024
Pediatric Psychiatry, Tropical Texas Behavioral Health, Harlingen, USA.
Obsessive-compulsive disorder (OCD), characterized by persistent, intrusive thoughts (obsessions) and repetitive behaviors or mental acts (compulsions), can significantly impact a child's daily functioning, academic performance, and overall quality of life. As the prevalence of pediatric OCD continues to rise, there is a critical demand for evidence-based treatments that not only alleviate symptoms but also enhance the quality of life for affected children and adolescents. By identifying gaps in knowledge and suggesting directions for future research, this narrative review contributes to the ongoing discourse on pediatric OCD treatments.
View Article and Find Full Text PDFA randomized controlled add-on trial of fluoxetine and cognitive behavioral therapy for help-seeking men with a sexual interest in children: presentation of the PARACHUTES trial protocol and initial feasibility data.
Front Psychiatry
August 2024
Department of Clinical Sciences/Psychiatry, Umeå University, Umeå, Sweden.
Background: Sexual Interest in Children (SIC) is a major risk factor for sexual offending, yet clinical trials are sparse. The present protocol outlines a randomized controlled trial (RCT) that aims to investigate the effectiveness of fluoxetine and Cognitive Behavioral Therapy (CBT) in help-seeking men with SIC.
Methods: Adult men contacting the Swedish telephone helpline PrevenTell are screened for inclusion and invited to further assessment on site.
Sertraline induced acute hepatocellular liver injury in patient with major depressive disorder: a case report.
Front Psychiatry
August 2024
Department of Psychiatry and Narcology, Riga Stradins University, Riga, Latvia.
This case report describes a patient with major depressive disorder (MDD) who developed acute hepatocellular liver injury after being treated with sertraline, a selective serotonin reuptake inhibitor (SSRI). The diagnosis of MDD was made two years prior, and the patient had previously responded partially to escitalopram and cognitive-behavioral therapy (CBT). Upon switching to sertraline 50 mg daily, the patient presented with severe symptoms indicative of acute liver injury, including elevated liver enzymes, jaundice, and gastrointestinal distress.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!